Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

Introduction/Background Anti-VEGF Dosing Regiments: Review of the Pertinent Studies Comparing the Anti-VEGF Dosing Strategies Conclusions References While ...

Kalaris is focused on developing TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased ...

Kalaris is focused on developing TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular and exudative dis ...

Obstructive sleep apnea is associated with higher rates of age-related macular degeneration development and progression.

Examples include: - Congestive heart failure - Liver cirrhosis - Nephrotic syndrome 2. *Exudative Pleural Effusion*: Caused by inflammation, infection, or malignancy, leading to fluid accumulation ...

Kalaris is currently developing TH103, a novel, differentiated anti-vascular endothelial growth factor ("VEGF”) agent engineered to potentially provide longer-lasting and increased anti-VEGF activity ...

The closing of the merger is expected to occur as soon as practicable, subject to the satisfaction or waiver of the remaining customary closing conditions. Following the closing of the merger, the ...